Literature DB >> 18687745

Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity.

T Kato1, J Shinoda, N Oka, K Miwa, N Nakayama, H Yano, T Maruyama, Y Muragaki, T Iwama.   

Abstract

BACKGROUND AND
PURPOSE: The relationship of (11)C-methionine (MET) uptake and tumor activity in low-grade gliomas (those meeting the criteria for World Health Organization [WHO] grade II gliomas) remains uncertain. The aim of this study was to compare MET uptake in low-grade gliomas and to analyze whether MET positron-emission tomography (PET) can estimate tumor viability and provide evidence of malignant transformation.
MATERIALS AND METHODS: We studied glioma metabolic activity in 49 consecutive patients with newly diagnosed grade II gliomas by using MET PET before surgical resection. On MET PET, we measured tumor/normal brain uptake ratio (T/N ratio) in 21 diffuse astrocytomas (DAs), 12 oligodendrogliomas (ODs), and 16 oligoastrocytomas (OAs). We compared MET T/N ratio among these 3 tumors and investigated possible correlation with proliferative activity, as measured by Mib-1 labeling index (LI).
RESULTS: MET T/N ratios of DA, OD, and OA were 2.11 +/- 0.87, 3.75 +/- 1.43, and 2.76 +/- 1.27, respectively. The MET T/N ratio of OD was significantly higher than that of DA (P < .005). In comparison of MET T/N ratios with the Mib-1 LI, a significant correlation was shown in DA (r = 0.63; P < .005) but not in OD and OA.
CONCLUSION: MET uptake in DAs may be closely associated with tumor viability, which depends on increased amino acid transport by an activated carrier-mediated system. DAs with lower MET uptake were considered more quiescent lesions, whereas DA with higher MET uptake may act more aggressively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18687745      PMCID: PMC8118949          DOI: 10.3174/ajnr.A1242

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  32 in total

1.  Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining.

Authors:  N Sato; M Suzuki; N Kuwata; K Kuroda; T Wada; T Beppu; K Sera; T Sasaki; A Ogawa
Journal:  Neurosurg Rev       Date:  1999-12       Impact factor: 3.042

2.  Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.

Authors:  B Kaschten; A Stevenaert; B Sadzot; M Deprez; C Degueldre; G Del Fiore; A Luxen; M Reznik
Journal:  J Nucl Med       Date:  1998-05       Impact factor: 10.057

Review 3.  Primary and secondary glioblastomas: from concept to clinical diagnosis.

Authors:  P Kleihues; H Ohgaki
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

4.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Authors:  M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

5.  Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.

Authors:  Soonmee Cha; Tarik Tihan; Forrest Crawford; Nancy J Fischbein; Susan Chang; Andrew Bollen; Sarah J Nelson; Michael Prados; Mitchel S Berger; William P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

Review 6.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

7.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

8.  Treatment and survival of low-grade astrocytoma in adults--1977-1988.

Authors:  B M McCormack; D C Miller; G N Budzilovich; G J Voorhees; J Ransohoff
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

9.  Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study.

Authors:  K Miwa; J Shinoda; H Yano; A Okumura; T Iwama; T Nakashima; N Sakai
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 10.  Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography.

Authors:  F T Vertosick; R G Selker; V C Arena
Journal:  Neurosurgery       Date:  1991-04       Impact factor: 4.654

View more
  33 in total

Review 1.  Current concepts in the evaluation and management of WHO grade II gliomas.

Authors:  Joseph M Piepmeier
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

2.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

3.  Differential kinetics of α-[¹¹C]methyl-L-tryptophan on PET in low-grade brain tumors.

Authors:  Csaba Juhász; Otto Muzik; Diane C Chugani; Harry T Chugani; Sandeep Sood; Pulak K Chakraborty; Geoffrey R Barger; Sandeep Mittal
Journal:  J Neurooncol       Date:  2010-07-30       Impact factor: 4.130

Review 4.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

5.  Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.

Authors:  Kentaro Kobayashi; Kenji Hirata; Shigeru Yamaguchi; Osamu Manabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Tohru Shiga; Naoya Hattori; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-08       Impact factor: 9.236

6.  Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with (18)F-FDG and (11)C-methionine: report of two cases.

Authors:  Shigeru Yamaguchi; Hiroyuki Kobayashi; Kenji Hirata; Tohru Shiga; Shinya Tanaka; Junichi Murata; Shunsuke Terasaka
Journal:  J Neurooncol       Date:  2010-06-15       Impact factor: 4.130

7.  PET findings of intramedullary tumors of the spinal cord using [18F] FDG and [11C] methionine.

Authors:  N Tomura; Y Ito; H Matsuoka; T Saginoya; S-I Numazawa; Y Mizuno; K Watanabe
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-28       Impact factor: 3.825

Review 8.  Value of 11C-methionine PET in imaging brain tumours and metastases.

Authors:  Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

9.  Characteristics of time-activity curves obtained from dynamic 11C-methionine PET in common primary brain tumors.

Authors:  Yuichi Nomura; Yoshitaka Asano; Jun Shinoda; Hirohito Yano; Yuka Ikegame; Tomohiro Kawasaki; Noriyuki Nakayama; Takashi Maruyama; Yoshihiro Muragaki; Toru Iwama
Journal:  J Neurooncol       Date:  2018-03-21       Impact factor: 4.130

10.  Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.

Authors:  Atsushi Watanabe; Yoshihiro Muragaki; Takashi Maruyama; Jun Shinoda; Yoshikazu Okada
Journal:  J Neurooncol       Date:  2015-11-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.